The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Sienna Biopharmaceuticals, Inc. on December 10, 2019. The debtor has been authorized to sell substantially all its assets to Sebacia, Inc, for a purchase price of $1.70 million in cash. At the auction held, Sebacia, Inc., emerged as the winning bidder by offering a purchase price of $1.70 million.